A dynamic HIV-transmission model for evaluating the costs and benefits of vaccine programs

Interfaces

Volumn 28, Issue 3, 1998, Pages 144-166

  Edwards, Donna M ^a   Shachter, Ross D ^b   Owens, Douglas K ^c  

^a SANDIA NATIONAL LABORATORIES   (United States)

^b STANFORD UNIVERSITY   (United States)

^c VA PALO ALTO HEALTH CARE SYSTEM   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 0039995150     PISSN: 00922102     EISSN: None     Source Type: Journal    
DOI: 10.1287/inte.28.3.144     Document Type: Article

References (46)

1. Anderson, R. M.; Gupta, S.; and May, R. M. 1991, "Potential of community-wide chemotherapy or immunotherapy to control the spread of HIV-1," Nature, Vol. 350, No. 6316, pp. 356-359.
2. Beck, J. R. and Pauker, S. G. 1983, "The Markov process in medical prognosis," Medical Decision Making, Vol. 3, No. 4, pp. 419-458.
3. Blower, S. M. and McLean, A. R. 1994, "Prophylactic vaccines, risk behavior change, and the probability of eradicating HIV in San Francisco," Science, Vol. 265, No. 5117, pp. 1451-1454.
4. Brandeau, M. L. and Owens, D. K. 1994, "When women return to risk: Costs and benefits of HIV screening in the presence of relapse," in Modeling the AIDS Epidemic: Planning, Policy and Prediction, eds. M. L. Brandeau and E. H. Kaplan, Raven Press, New York, pp. 121-136.
5. Brandeau, M. L.; Owens, D. K.; Sox, C. H.; and Wachter, R. M. 1992, "Screening women of childbearing age for human immunodeficiency virus: A cost-benefit analysis," Archives of Internal Medicine, Vol. 152, pp. 2229-2237.
6. Brandeau, M. L.; Owens, D. K.; Sox, C. H.; and Wachter, R. M. 1993, "Screening women of childbearing age for human immunodeficiency virus: a model-based policy analysis," Management Science, Vol. 39, No. 1, pp. 72-92.
7. Chan, C. M. and Oreglia, A. 1993, California Life Expectancy: Abridged Life Tables for California and Los Angeles County 1989-91, California Department of Health Services, Sacramento, California, August.
8. Cohen, J. 1994, "HIV vaccines: Are researchers racing toward success, or crawling?" Science, Vol. 265, No. 5177, pp. 1373-1375.
9. Communication Technologies in association with the San Francisco AIDS Foundation. 1990, "HIV-related knowledge, attitudes, and behaviors among San Francisco gay and bisexual men: Results from the fifth population-based survey," San Francisco Department of Public Health report, January 30.
10. DiClemente, R. J. and Wingood, G. M. 1995, "A randomized controlled trial of an HIV sexual risk-reduction intervention for young African-American women," Journal of the American Medical Association, Vol. 274, No. 16, pp. 1271-1276.
11. Dolin, R.; Graham, B. S.; Greenberg, S. B.; Tacket, C. O.; Belshe, R. B.; Midthun, K.; Clements, M. L.; Gorse, G. J.; Horgan, B. W.; Atmar, R. L.; Karzon, D. T.; Bonnez, W.; Fernie, B. F.; Montefiori, D. C.; Stablein, D. M.; Smith, G. E.; Koff, W. C.; and NIAD AIDS Vaccine Clinical Trials Network 1991, "The safety and immunogenicity of a human immunodeficiency virus type 1 (HIV-1) recombinant gp160 candidate vaccine in humans," Annals of Internal Medicine, Vol. 114, No. 2, pp. 119-127.
12. Edwards, D. M. 1995, "A cost-effectiveness analysis of potential preventive and therapeutic HIV vaccines," PhD thesis, Department of Engineering-Economic Systems, Stanford University.
13. Edwards, D. M.; Shachter, R. D.; and Owens, D. K. 1995a, "Comparison of methods for valuing health and economic effects of interventions with delayed outcomes: application to HIV vaccine programs," Medical Decision Making, Vol. 15, No. 4, p. 420.
14. Edwards, D. M.; Shachter, R. D.; and Owens, D. K. 1995b, "Cost effectiveness of preventive and therapeutic HIV vaccines: Implications for vaccine development" (abstract), Medical Decision Making, Vol. 15, No. 4, p. 420.
15. Graham, B. S.; Keefer, M. C.; McElrath, J.; Gorse, G. J.; Schwartz, D. H.; Weinhold, K.; Matthews, T. J.; Sinangil, F.; Esterlitz, J. R.; and Fast, P. E. 1996, "Safety and immunogenicity of a candidate HIV-1 vaccine in healthy adults: Recombinant glycoprotein (rgp) 120," Annals of Internal Medicine, Vol. 125, No. 4, pp. 270-279.
16. Graham, B. S. and Wright, P. F. 1995, "Candidate AIDS vaccines," New England Journal of Medicine, Vol. 333, No. 20, pp. 1331-1339.
17. Haynes, B. F. 1993, "Scientific and social issues of human immunodeficiency virus vaccine development," Science, Vol. 260, No. 5112, pp. 1279-1286.
18. Haynes, B. F.; Pantaleo, G.; and Fauci, A. S. 1996, "Toward an understanding of the correlates of protective immunity to HIV infection," Science, Vol. 271, No. 5247, pp. 324-328.
19. Hellinger, F. J. 1992, "Forecasts of the costs of medical care for persons with HIV: 1992-1995," Inquiry, Vol. 29, No. 3, pp. 356-365.
20. Hellinger, F. J. 1993, "The lifetime cost of treating a person with HIV," Journal of the American Medical Association, Vol. 270, No. 4, pp. 474-478.
21. Laumann, E. O.; Gagnon, J. H.; Michael, R. T.; and Michaels, S. 1994, The Social Organization of Sexuality: Sexual Practices in the United States, The University of Chicago Press, Chicago, Illinois.
22. Lemp, G. F.; Payne, S. F.; Rutherford, G. W.; Hessol, N. A.; Winkelstein, W. J.; Wiley, J. A.; Moss, A. R.; Chaisson, R. E.; Chen, R. T.; Feigal, D. W. J.; Thomas, P. A.; and Werdegar, D. 1990, "Projections of AIDS morbidity and mortality in San Francisco," Journal of the American Medical Association, Vol. 263, No. 11, pp. 1497-1501.
23. Longini, I. M., Jr.; Clark, W. S.; Byers, R. H.; Ward, J. W.; Darrow, W. W.; Lemp, G. F.; and Hethcote, H. W. 1989, "Statistical analysis of the stages of HIV infection using a Markov model," Statistics in Medicine, Vol. 8, No. 7, pp. 831-843.
24. The MathWorks, I 1992, The Student Edition of MATLAB, Prentice Hall, Englewood Cliffs, New Jersey.
25. The MathWorks, I 1994, "MATLAB," version 4.2c for UNIX, The MathWorks, Inc., Natick, Massachusetts.
26. McLean, A. R. and Blower, S. M. 1993, "Imperfect vaccines and herd immunity to HIV," Proceedings of the Royal Society of London. Series B: Biological Sciences, Vol. 253, pp. 9-13.
27. Newcomb, M.; Liu, W.; Officer, C.; Hulbert, L.; Wallis, J.; Richmond, K.; and Richmond, B. 1996, "Stella II," PC version 3.0.7 for Windows, High Performance Systems, Inc., Hanover, New Hampshire.
28. Owens, D. K.; Cardinalli, A. B.; and Nease, R. F., Jr. 1997, "Physicians' assessments of the utility of health states associated with human immunodeficiency virus (HIV) and hepatitis B virus (HBV) infection," Quality of Life Research, Vol. 6, No. 1, pp. 77-86.
29. Owens, D. K.; Edwards, D. M.; and Shachter, R. 1996, "Population effects of preventive and therapeutic HIV vaccine in early- and late-stage epidemics," Report No. SMI-97-0674, Department of Medicine, Section on Medical Informatics, Stanford University.
30. Owens, D. K.; Harris, R. A.; Scott, P. M.; and Nease, R. F., Jr. 1995, "Screening surgeons for HIV infection: A cost-effectiveness analysis," Annals of Internal Medicine, Vol. 122, No. 9, pp. 641-652.
31. Owens, D. K. and Nease, R. F. 1994, "Transmission of human immunodeficiency virus (HIV) infection between provider and patient: A quantitative analysis of risk," in Modeling the AIDS Epidemic: Planning, Policy and Prediction, eds. M. L. Brandeau and E. H. Kaplan, Raven Press, New York, pp. 153-177.
32. Owens, D. K. and Sox, H. C., Jr. 1990, "Medical decision making: Probabilistic medical reasoning," in Medical Informatics: Computer Applications in Health Care, eds. E. H. Shortliffe, L. E. Perreault, L. M. Fagan, and G. Wiederhold, Addison-Wesley, Reading, Massachusetts, pp. 70-116.
33. Paltiel, A. D. 1994, "Timing is of the essence: Matching AIDS policy to the epidemic life cycle," in Modeling the AIDS Epidemic: Planning, Policy and Prediction, eds. M. L. Brandeau and E. H. Kaplan, Raven Press, New York, pp. 53-72.
34. Paltiel, A. D. and Kaplan, E. H. 1991, "Modeling zidovudine therapy: A cost-effectiveness analysis," Journal of Acquired Immune Deficiency Syndromes, Vol. 4, No. 8, pp. 795-804.
35. Paltiel, A. D. and Kaplan, E. H. 1993, "The epidemiological and economic consequences of AIDS clinical trials," Journal of Acquired Immune Deficiency Syndromes, Vol. 6, No. 2, pp. 179-190.
36. Redfield, R. R.; Birx, D. L.; Ketter, N.; Tramont, E.; Polonis, V.; Davis, C.; Brundage, J. F.; Smith, G.; Johnson, S.; Fowler, A.; Wierzba, T.; Shafferman, A.; Volvovitz, F.; Oster, C.; Burke, D. S.; and Military Medical Consortium for Applied Retroviral Research 1991, "A phase I evaluation of the safety and immunogenicity of vaccination with recombi-nant gp160 in patients with early human immunodeficiency virus infection," New England Journal of Medicine, Vol. 324, No. 24, pp. 1677-1684.
37. Samuel, M. C.; Mohr, M. S.; Speed, T. P.; and Winkelstein, W., Jr. 1994, "Infectivity of HIV by anal and oral intercourse among homosexual men: Estimates from a prospective study in San Francisco," in Modeling the AIDS Epidemic: Planning, Policy and Prediction, eds. M. L. Brandeau and E. H. Kaplan, Raven Press, New York, pp. 423-438.
38. San Francisco Department of Public Health 1992, "HIV incidence and prevalence in San Francisco in 1992: Summary report from an HIV consensus meeting." San Francisco Department of Public Health, San Francisco, California, February 2, p. 3.
39. San Francisco Department of Public Health 1995, "AIDS Surveillance Report," San Francisco Department of Public Health, San Francisco, California, April 30, p. 3.
40. Shepard, D. S. and Thompson, M. S. 1979, "First principles of cost-effectiveness analysis in health," Public Health Reports, Vol. 94, No. 6, pp. 535-543.
41. Sonnenberg, F. A. and Beck, J. R. 1993, "Markov models in medical decision making: A practical guide," Medical Decision Making, Vol. 13, No. 4, pp. 322-338.
42. Trussell, J.; Hatcher, R. A.; Cates, W., Jr.; Stewart, F. H.; and Kost, K. 1990, "A guide to interpreting contraceptive efficacy studies," Obstetrics and Gynecology, Vol. 76, No. 3, pt. 2, pp. 558-67.
43. Weinstein, M. C. and Stason, W. B. 1977, "Foundations of cost-effectiveness analysis for health and medical practices," New England Journal of Medicine, Vol. 296, No. 13, pp. 716-721.
44. WHO/UNAIDS 1996, "The current global situation of AIDS," World Health Organization (available from the Regional Program on AIDS/STD, Pan American Health Organization, 525 23rd St. NW, Washington, DC 20037-2847), June 30.
45. Wintsch, J.; Chaignat, C.-L.; Braun, D. G.; Jeannet, M.; Stalder, H.; Abrignani, S.; Montagna, D.; Clavijo, F.; Moret, P.; Dayer, J.-M.; Staehelin, T.; Doe, B.; Steimer, K. S.; Dina, D.; and Cruchaud, A. 1991, "Safety and immunogenicity of a genetically engineered human immunodeficiency virus vaccine," Journal of Infectious Diseases, Vol. 163, No. 2, pp. 219-225.
46. World Health Organization 1995, "Scientific and public health rationale for HIV vaccine efficacy trials," AIDS, Vol. 9, No. 3, pp. WHO1-WHO4.